February’s top stories: Thermo Fisher’s $13.6bn deal, Medtronic’s leadless pacemaker
Thermo Fisher Scientific completed its acquisition of Life Technologies, a life sciences company, for approximately $13.6bn, while Medtronic reported the first implant of vitamin-sized leadless pacemaker in US. Medicaldevice-network.com wraps-up the key headlines from February 2014.
Qiagen rolled-out its careHPV Test, a new molecular diagnostic test for high-risk human papillomavirus (HPV), in India.
The portable and easy-to-use careHPV test has colour-coded, easy-to-understand menus and self-contained reagents.
The test is designed to screen women in settings with limited healthcare infrastructure, such as areas lacking electricity, water or laboratories. It is also capable of tolerating variations in the temperature that occur in rural clinics lacking refrigeration for sample storage due to limited electricity or water.
Johnson & Johnson subsidiary Cordis obtained European CE Mark for its Renlane renal denervation system designed for the treatment of adult patients (>18 years) with drug-resistant hypertension to denervate the renal arteries to reduce blood pressure.
The Renlane renal denervation catheter features five irrigated electrodes located at the tip of the ablation catheter and is used in conjunction with the Renlane Multi-Channel RF generator for energy delivery.
The Renlane system includes a helical shaped, irrigated, multi-electrode ablation catheter with a multi-channel radiofrequency ablation system.
Hong Kong-based OrbusNeich initiated patient enrolment in the HARMONEE study being conducted for evaluating the Combo dual-therapy stent, designed to address the challenges of delayed healing of the coronary artery associated with monotherapy drug-eluting stents in Japan.
It is reportedly the first dual-therapy stent to both accelerate endothelial coverage and control neointimal proliferation through the combination of a proven pro-healing technology with an abluminal sirolimus drug elution delivered from a biodegradable polymer that achieves complete dissipation by 90 days.
The technology is composed of an antibody surface coating that captures endothelial progenitor cells (EPCs) to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.
Medtronic announced that its Micra transcatheter pacing system (TPS) has been implanted in the first patient in the US, as part of the company's single-arm, multi-centre global clinical trial.
It was successfully implanted at NYU Langone Medical Center by Dr Larry Chinitz, director of the Heart Rhythm Center at NYU Langone Medical Center in New York City.
"Eliminating the need for a lead and pocket has the potential to reduce complications and recovery times compared with traditional pacemaker implants, which would be a major benefit to patients," Dr Chinitz said.
US-based Boston Scientific received CE Mark in Europe for its WallFlex esophageal fully covered stent, designed to treat refractory benign esophageal strictures, a narrowing of the esophagus caused by scar tissue.
The WallFlex esophageal fully covered stent uses a proprietary Permalume silicone covering to prevent tumour ingrowth, seal concurrent esophageal fistulas and helps reduce food impaction.
The stent is designed for gradual expansion, typically complete after 24 to 72 hours and its progressive-step, flared ends are intended to minimise the risk of migration and may assist in anchoring the fully covered stent within the esophageal lumen.
Xerox researchers designed a new medical technology that uses video cameras and data analytics to monitor a patient's condition without wires, discomfort or risk of infection.
Using patented software algorithms, Xerox researchers have been able to convert data collected by the cameras into vital signs.
The light emitted from the camera penetrates into the patient's skin, allowing information to be captured and converted to health indicators.
Thermo Fisher Scientific completed its acquisition of Life Technologies, a life sciences company, for approximately $13.6bn and the assumption of $1.5bn in net debt.
The completion of this deal comes after the US Federal Trade Commission cleared the deal with the condition that Thermo Fisher sell certain assets related to siRNA reagents, cell culture media, and cell culture sera to GE Healthcare for $1.06bn.
The company anticipates that this acquisition will create enhanced scale and depth of capabilities for customers working in research, specialty diagnostics and applied markets.
Smith & Nephew agreed to buy ArthroCare for $48.25 per ArthroCare share in cash, a total consideration of approximately $1.7bn and an enterprise value of $1.5bn, as part of its strategy to strengthen its global sports medicine business.
The acquisition will be subject to customary conditions, including a vote of ArthroCare's shareholders and governmental clearances.
Pending the satisfaction of such customary conditions, Smith & Nephew expects to close the deal in mid-2014.